-
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
NASDAQ: $IRON WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious… Source: Read More
-
Breakthrough Results: Encaleret Shows Promise for Autosomal Dominant Hypocalcemia Type 1
NASDAQ: $BBIO A New Frontier in Treating ADH1 Recent results from the Phase 3 CALIBRATE trial have brought a wave of optimism for patients living with Autosomal Dominant Hypocalcemia Type 1 (ADH1). The trial evaluated the efficacy and safety of encaleret, an investigational therapy designed to address the underlying physiological challenges of this rare genetic…
-
New Hope on the Horizon: Bristol Myers Squibb Launches Phase 3 ALOFT Trial for IPF
NYSE: $BMY A New Frontier in Pulmonary Research The fight against Idiopathic Pulmonary Fibrosis (IPF), a progressive and chronic lung disease, has reached a significant milestone. Bristol Myers Squibb has officially announced the initiation of the Phase 3 ALOFT clinical trial, a critical step in evaluating the efficacy and safety of a potential new treatment:…
-
A New Frontier in Colon Cancer: First Patient Dosed in Phase III Cadonilimab Trial
Advancing Immunotherapy for Colon Cancer In a significant milestone for oncology research, Akeso, Inc. has officially announced that the first patient has been dosed in a global Phase III clinical trial evaluating cadonilimab. This study focuses on the perioperative treatment of patients with locally advanced colon cancer. Understanding Cadonilimab Cadonilimab is a novel, potentially first-in-class…
-
A Breakthrough in Sight: Amgen Announces Positive Phase 3 Results for Dazodalibep
NASDAQ: $AMGN Promising News for Sjögren’s Syndrome Patients There is a significant glimmer of hope for individuals living with moderate-to-severe systemic Sjögren’s syndrome. Amgen has officially announced positive topline results from their Phase 3 clinical trial evaluating dazodalibep, an investigational medicine designed to address the symptoms of this challenging autoimmune condition. Understanding the Clinical Trial…
-
A Breakthrough for ALS: Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen
A New Horizon for ALS Patients The Amyotrophic Lateral Sclerosis (ALS) community has received promising news as Otsuka Pharmaceutical announced the top-line results from its Phase 3 FUSION clinical trial. The study evaluated the efficacy and safety of ulefnersen, an investigational treatment designed to address the underlying challenges faced by patients living with this neurodegenerative…
-
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-Positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
South San Francisco, CA — September 30, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with… Source: Read More
-
Boehringer Ingelheim’s Survodutide Achieves up to 13.1% Weight Loss in New Phase III Trial, Alongside Significant Improvements in Glycemic Control in People with Obesity and Type 2 Diabetes
Ingelheim, Germany, October 1, 2026 — Boehringer Ingelheim today announced positive results from the Phase III SYNCHRONIZE-2 trial, which investigates the glucagon/GLP-1 receptor dual agonist survodutide (BI 456906) in adults living with… Source: Read More
-
Zasocitinib Shows Superior Efficacy Over Deucravacitinib in New Phase 3 Trial
NYSE: $TAK A Breakthrough in Psoriasis Treatment New clinical data has emerged that could reshape the treatment landscape for plaque psoriasis. Recent Phase 3 head-to-head study results demonstrate that zasocitinib has achieved superior efficacy compared to deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. Understanding the Clinical Results The study, which directly compared the two…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 08-30-2026 TO 09-05-2026
I’m excited to announce the release of my latest FREE bio tech stock catalyst report for the upcoming week. This new FREE stock report highlights bio tech companies that have an important upcoming event and an expected price move of 20 percent up or down ($ +/- 20%) to help you make informed market decisions.…